Leerink downgraded Reneo Pharmaceuticals to Market Perform from Outperform with a $1 price target. The downward follows the company announcing that its pivotal STRIDE study of mavodelpar in adult patients with primary mitochondrial myopathies did not meet its primary efficacy or secondary efficacy endpoint.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on RPHM:
- Reneo Pharmaceuticals Announces Results from Pivotal STRIDE Study of Mavodelpar in Primary Mitochondrial Myopathies (PMM)
- Block upgraded, Bristol Myers downgraded: Wall Street’s top analyst calls
- Reneo Pharmaceuticals initiated with an Outperform at William Blair
- Reneo Pharmaceuticals files $300M mixed securities shelf
- Reneo Pharmaceuticals reports Q3 EPS (57c), consensus (57c)